ATE422894T1 - Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom - Google Patents

Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom

Info

Publication number
ATE422894T1
ATE422894T1 AT03718033T AT03718033T ATE422894T1 AT E422894 T1 ATE422894 T1 AT E422894T1 AT 03718033 T AT03718033 T AT 03718033T AT 03718033 T AT03718033 T AT 03718033T AT E422894 T1 ATE422894 T1 AT E422894T1
Authority
AT
Austria
Prior art keywords
prostaglandin
glaucoma
treatment
analoga
alpha
Prior art date
Application number
AT03718033T
Other languages
English (en)
Inventor
Kirk Maxey
Jennifer Johnson
Original Assignee
Cayman Chem Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cayman Chem Co filed Critical Cayman Chem Co
Application granted granted Critical
Publication of ATE422894T1 publication Critical patent/ATE422894T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT03718033T 2002-03-21 2003-03-21 Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom ATE422894T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36707102P 2002-03-21 2002-03-21

Publications (1)

Publication Number Publication Date
ATE422894T1 true ATE422894T1 (de) 2009-03-15

Family

ID=28454834

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03718033T ATE422894T1 (de) 2002-03-21 2003-03-21 Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom

Country Status (7)

Country Link
US (1) US20060264353A1 (de)
EP (1) EP1501530B1 (de)
JP (1) JP2005526092A (de)
AT (1) ATE422894T1 (de)
AU (1) AU2003222049B2 (de)
DE (1) DE60326226D1 (de)
WO (1) WO2003079997A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
JP2003520195A (ja) * 1999-05-14 2003-07-02 イムクローン システムズ インコーポレイティド 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理
AU2001295002B2 (en) * 2000-08-09 2007-05-31 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
EP1622941A2 (de) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Methode zur produktion von anti-egfr antikörpern
US7598350B2 (en) * 2004-03-19 2009-10-06 Imclone Llc Human anti-epidermal growth factor receptor antibody
US20070015838A1 (en) * 2005-07-14 2007-01-18 Allergan, Inc. Cyclopentane n-lower alkyl heptenamide-5-cis-2-(3alpha-hydroxy-5-phenylpentyl)-3, 5-dihydroxy, [1alpha, 2beta, 3alpha, 5alpha] compounds as agents for lowering intraocular pressure
JP2009504689A (ja) * 2005-08-16 2009-02-05 ユニバーシティ オブ コペンハーゲン Ｇｄｎｆ由来ペプチド
EP1941876A1 (de) * 2006-12-28 2008-07-09 Lacer, S.A. Isosorbidmononitrit Derivate zur Behandlung von der Inflammation und okularen Hypertension
US20100266710A1 (en) * 2007-07-26 2010-10-21 Mihran Baronian Pharmaceutical preparations comprising electrochemically activated hypochlorite solutions
CA2710822C (en) 2008-01-07 2022-06-14 Johannes Gerhardus Maria Bolscher Use of histatin derived peptides for promoting wound healing
US9090670B2 (en) 2008-01-07 2015-07-28 Rapid Pathogen Screening, Inc. Use of peptides for promoting wound healing
CN102099006B (zh) * 2008-05-14 2014-07-09 彼得托马斯罗思实验室有限责任公司 前列腺素型组合物和其使用方法
DE102009007381A1 (de) * 2009-01-29 2010-08-05 Amp-Therapeutics Gmbh & Co. Kg Antibiotische Peptide
KR101724171B1 (ko) * 2009-09-09 2017-04-06 파마인 코포레이션 치료제 전달용 음이온-코어 조성물, 및 이를 제조 및 사용하는 방법
US20130310326A1 (en) * 2012-05-18 2013-11-21 Rapid Pathogen Screening, Inc. Histatin for Corneal Wound Healing and Ocular Surface Disease
CN105592851A (zh) * 2013-09-30 2016-05-18 帕西昂Api服务公司 利用复分解反应的前列腺素和前列腺素中间体的新合成途径
JP2017502089A (ja) 2014-01-10 2017-01-19 マニスティー パートナーズ エルエルシーＭａｎｉｓｔｅｅ Ｐａｒｔｎｅｒｓ Ｌｌｃ 偏頭痛の処置
MX355853B (es) * 2014-06-20 2018-05-02 Coopervision Int Holding Co Lp Composicion oftalmica para el tratamiento de infeccion ocular.
IT201700006360A1 (it) * 2017-01-20 2018-07-20 Italdevice Srl Composizione per uso oftalmico
US20230114656A1 (en) * 2021-10-08 2023-04-13 Jds Therapeutics, Llc Products and methods for extending the shelf life of water sensitive products

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049678A (en) * 1976-03-29 1977-09-20 The Upjohn Company 9-Deoxy-PGD-type, 1,15-lactones
US4049648A (en) * 1975-06-23 1977-09-20 The Upjohn Company PG-type, 1,9-lactones
US4025516A (en) * 1975-06-23 1977-05-24 The John C. Sheehan Institute For Research, Inc. Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans
US4116979A (en) * 1975-06-23 1978-09-26 Sheehan Institute For Research, Inc. Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans
JP3361830B2 (ja) * 1992-03-30 2003-01-07 生化学工業株式会社 抗菌性組成物及びそれを有効成分とする薬剤
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5652209A (en) * 1994-04-29 1997-07-29 University Of Miami Use of secretory products of human lacrimal gland acinar epithelia for tear replacement therapy
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
DE69834638T2 (de) * 1997-10-13 2007-05-10 R-Tech Ueno, Ltd. Zusammensetzung zur Behandlung von Augenhypertension oder Glaukom
IL153556A0 (en) * 2000-06-28 2003-07-06 Univ Iowa Res Found Novispirins: antimicrobial peptides
US20020035148A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension
US20030018079A1 (en) * 2000-11-13 2003-01-23 Richardson Helene Treatment

Also Published As

Publication number Publication date
EP1501530A4 (de) 2006-05-03
EP1501530B1 (de) 2009-02-18
EP1501530A2 (de) 2005-02-02
DE60326226D1 (de) 2009-04-02
AU2003222049A1 (en) 2003-10-08
AU2003222049B2 (en) 2007-05-31
WO2003079997A3 (en) 2004-02-12
WO2003079997A2 (en) 2003-10-02
US20060264353A1 (en) 2006-11-23
JP2005526092A (ja) 2005-09-02

Similar Documents

Publication Publication Date Title
ATE422894T1 (de) Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom
ES2458493T8 (es) Composición oftálmica tópica de fluprostenol para el tratamiento del glaucoma y de la hipertensión ocular
BR0310047A (pt) Análogos de 8-azaprostaglandina como agentes para diminuição de pressão intra-ocular
GEP20094780B (en) Prostaglandin nitrooxyderivatives
US20070004640A1 (en) Treatment of dry eye
ES2178291T3 (es) Uso de acidos 3-benzoil-aceticos, esteres, o amidas para el tratamiento del glaucoma glc1a.
WO2000027424B1 (en) Upregulation of endogenous prostaglandins to lower intraocular pressure
WO2006047744A3 (en) Compositions of lactoferrin related peptides and uses thereof
BR0209709A (pt) Composições hipotensivas de lipìdio e timolol e métodos de uso das mesmas
RU2004134733A (ru) Агенты, которые регулируют, ингибируют или модулируют активность и/или экспрессию факторов роста соединительной ткани (фрст), в качестве уникальных средств для снижения внутриглазного давления и лечения глаукоматозных ретинопатий/оптических невропатий
WO2002098345A8 (fr) Utilisation d'un antioxydant pour le traitement et/ou la prevention des affections oculaires de surface
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
DE69719931D1 (de) Verwendung von Acetylcystein zur Herstellung eines Arzneimittels zur Behandlung von chronischen Geschwüren
WO2003072066A3 (en) Compositions and methods for the treatment of glaucoma and ocular hypertension
EP1915998A8 (de) Prophylaktisches oder therapeutisches mittel gegen hornhaut/bindehaut-erkrankungen
ATE169815T1 (de) Ophthalmische zusammensetzungen enthaltend als wirkstoff vitamin-e oder ester davon
ATE78031T1 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
ATE453395T1 (de) 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
FR2754712B1 (fr) Compositions ophtalmiques
BR0315864A (pt) Composições e processos para a modificação efeitos tóxicos de compostos proteináceos
ATE428684T1 (de) Verwendung von bisaminen zur verstärkung der antimikrobiellen wirkung von wässrigen zusammensetzungen
AU687906B2 (en) Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
ATE326972T1 (de) Heilende zusammensetzung für intraokulare hypertension oder glaukom
KR970701044A (ko) 콜린에스테라제 활성제
WO1995034302A3 (en) Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties